

CLINICAL STUDY PROTOCOL

F901318C20

EudraCT No. 2016-000919-33

An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of intravenous and oral F901318 (combined with caspofungin) for antifungal prophylaxis in patients undergoing chemotherapy for acute myeloid leukaemia (SAFEGUARD)

This study was submitted to authorities, however the study was stopped without any subjects being recruited; therefore, no report was created.

DocuSigned by:
John Rex
Signer Name: John Rex
Signing Reason: I approve this document
Signing Time: 01-Mar-22 | 20:25 GMT
C1091C03E0FB49F49C58AEBB0414ABA5

John Rex
Chief Medical Officer

F2G Limited
Lankro Way, Eccles
Manchester, M30 0LX
United Kingdom
[+44 \(0\)161 785 1270](tel:+441617851270)
contact@f2g.com
Registered in England and Wales No: 03578625
VAT: GB 712680645

F2G Biotech GmbH
Seilerstätte 17/13
1010 Vienna
Austria
[+43 \(0\)1 997 4267](tel:+4319974267)
office-AT@f2g.com
Firmenbuchnummer: FN 483749 x
VAT: ATU73283369